Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

References

• Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:189-209
   PubMed Web of Science ®Google Scholar
• Erwin AL, Smith AL. Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol 2007;15:355-62
   PubMed Web of Science ®Google Scholar
• Sarangi J, Cartwright K, Stuart J, et al. Invasive Haemophilus influenzae disease in adults. Epidemiol Infect 2000;124:441-7
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev 1991;13:113-42
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or = 65 years old. Clin Infect Dis 2007;44:810-6
   PubMed Web of Science ®Google Scholar
• Vuori-Holopainen E, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis 2001;32:715-26
   PubMed Web of Science ®Google Scholar
• Murphy TF. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 2003;16:129-34
   PubMed Web of Science ®Google Scholar
• Erwin AL, Nelson KL, Mhlanga-Mutangadura T, et al. Characterization of genetic and phenotypic diversity of invasive nontypeable Haemophilus influenzae. Infect Immun 2005;73:5853-63
   PubMed Web of Science ®Google Scholar
• Heath PT, Booy R, Azzopardi HJ, et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 2001;20:300-5
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae disease, Europe, 1996–2006. Emerg Infect Dis 2010;16:455-63
   PubMed Web of Science ®Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17
   PubMed Web of Science ®Google Scholar
• European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network. Invasive Haemophilus influenzae in Europe 2006
   Google Scholar
• Perdue DG, Bulkow LR, Gellin BG, et al. Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 2000;283:3089-94
   PubMed Web of Science ®Google Scholar
• Bekri H, Cohen R, Varon E, et al. Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pediatr 2007;14:239-43
   PubMed Web of Science ®Google Scholar
• Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006;25:250-4
   PubMed Web of Science ®Google Scholar
• Fletcher M, Leeming J, Cartwright K, et al. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2006;25:559-60
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21
   PubMed Web of Science ®Google Scholar
• PneumoADIP. Pneumococcal regional serotype distribution for Pneumococcal AMC TPP
   Google Scholar
• Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8
   PubMed Web of Science ®Google Scholar
• Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 2009;8:977-86
   PubMed Web of Science ®Google Scholar
• Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination–a review (2002–2006). Vaccine 2007;25:1355-67
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson L, Poirier B, et al. How to compare the efficacy of conjugate vaccines to prevent acute otitis media? Vaccine 2009;27:2877-83
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Available at: http://www.statcan.gc.ca. Accessed October 2008
   Google Scholar
• UK National Statistics. Population. Available at: http://www.statistics.gov.uk/hub/population/index.html. Accessed September 2009
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73:889-97
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, et al. Invasive pneumococcal infections in Canadian children, 1998–2003: implications for new vaccination programs. Can J Public Health 2007;98:111-5
   PubMed Web of Science ®Google Scholar
• Talbird SE, Taylor TN, Knoll S, et al. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2010;28(6 Suppl):G23-9
   Google Scholar
• Health Protection Agency. Pneumococcal serotype distribution for samples referred for serotyping epidemiological years (July–June): 2000/1 – 2005/6. Available at: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733824984?p=1203409671918. Accessed June 2009
   Google Scholar
• Denham BC, Clarke SC. Serotype incidence and antibiotic susceptibility of Streptococcus pneumoniae causing invasive disease in Scotland, 1999–2002. J Med Microbiol 2005;54:327-31
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Complete life table, Canada, 2000–2002. Table 2a males, Table 2b females. Catalogue No. 84-537-XIE. Available at: http://www.statcan.ca/english/freepub/84-537-XIE/tables.htm. [Last accessed September 2008]
   Google Scholar
• NHS. Routine childhood immunisations from Spring 2010. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_120269.pdf. Accessed November 2010
   Google Scholar
• Public Health Agency of Canada. Publicly funded immunization programs in Canada - Routine schedule for infants and children (including special programs and catch-up programs) 2010-09-23. Available at: http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php. Accessed March 2011
   Google Scholar
• Spratt JS Jr. The relation of 'human capital' preservation to health costs. Am J Econ Sociol 1975;34:295-307
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold M, Siegel J, Russel L, et al, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. p 214-47
   Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. Issue date: June 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed November 2010
   Google Scholar
• Poirier B, De Wals P, Petit G, et al. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2009;27:7105-9
   PubMed Web of Science ®Google Scholar
• Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007;18:121-7
   PubMed Web of Science ®Google Scholar
• Health Protection Agency. Number of laboratory confirmed invasive pneumococcal disease cases (including meningitis) in England and Wales, 1996–2005. Available at: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733751944?p=1203409671918. Accessed April 2008
   Google Scholar
• Johnson AP, Waight P, Andrews N, et al. Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England. J Infect 2007;55:394-9
   PubMed Web of Science ®Google Scholar
• Jette LP, Lamothe F. Surveillance of invasive Streptococcus pneumonia infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 1989;27:1-5
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004;22:4203-14
   PubMed Web of Science ®Google Scholar
• Petit G, De Wals P, Law B, et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003;14:215-20
   PubMedGoogle Scholar
• Office for National Statistics. Time series data: Mid-2006 population estimates: United Kingdom; estimated resident population by single year of age and sex
   Google Scholar
• Hospital Episode Statistics (HES). The NHS Information Centre for Health and Social Care. Primary diagnosis: 4 character. Available at: http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=214. [Last accessed September 2008]
   Google Scholar
• Williamson I, Benge S, Mullee M, et al. Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study. Br J Gen Pract 2006;56:170-5
   PubMed Web of Science ®Google Scholar
• De Wals P, Black S, Borrow R, et al. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin Ther 2009;31:2152-69
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502
   PubMed Web of Science ®Google Scholar
• Poolman J, Kriz P, Feron C, et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009;27:3213-22
   PubMed Web of Science ®Google Scholar
• Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM). Bacterial meningitis in the Netherlands; annual report 2007. Amsterdam: University of Amsterdam, 2008
   Google Scholar
• WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006;81:445-52
   Google Scholar
• Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5
   PubMed Web of Science ®Google Scholar
• Vemer P, de Greeff S, Schouls L, et al. Seven, ten, or thirteen? The cost-utility of infant vaccination with a 7-, 10- or 13-valent pneumococcal conjugate vaccine in the Netherlands. Value Health 2009;12:A228 [abstract VA1]. Abstract available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2009.00592_1.x/pdf. Presentation available at: https://www.ispor.org/awards/12euro/VA1.pdf. [Last accessed August 2011]
   Google Scholar
• Williamson I, Benge S, Mullee M, et al. Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study. Br J Gen Pract 2006;56:170-5
   PubMed Web of Science ®Google Scholar
• Thompson PL, Murray ML, Sharland M, et al. Up-to-date findings show change in acute otitis media consultation trend. Br J Gen Pract 2006;56:379-80
   PubMed Web of Science ®Google Scholar
• Rovers MM. The burden of otitis media. Vaccine 2008;26(7 Suppl):G2-4
   Google Scholar
• Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004;23:1142-52
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002;21:1008-16
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction–eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005;54:893-7
   PubMedGoogle Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009;28(4 Suppl):S89-96
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-76
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009;28(4 Suppl):S77-88
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
   PubMed Web of Science ®Google Scholar
• Bennett JE, Sumner 2nd W, Downs SM, et al. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000;154:43-8
   PubMedGoogle Scholar
• Oh PI, Maerov P, Pritchard D, et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996;18:160-82
   PubMed Web of Science ®Google Scholar
• Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004;113:283-90
   PubMed Web of Science ®Google Scholar
• Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010;28:7634-43
   PubMed Web of Science ®Google Scholar
• Curtis L. Unit costs of health & social care 2007. Canterbury: Personal Social Services Research Unit (PSSRU), University of Kent; 2007. Available at: http://www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf. Accessed August 2011
   Google Scholar
• Department of Health. National tariff 2006/07: payment by results. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4127649. Accessed August 2011
   Google Scholar
• Ontario Ministry of Health and Long Term Care. Schedule of benefits: physician services under the Health Insurance Act (July 1, 2011). Available at: http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html. [Last accessed August 2011]
   Google Scholar
• Russell P. Disabled children, their families and child poverty: briefing paper. London: Council for Disabled Children. Available at: http://www.leeds.ac.uk/disability-studies/archiveuk/every%20child/disabled_children_and_child_poverty.pdf. [Last accessed August 2011]
   Google Scholar
• National Collaborating Centre for Women’s and Children’s Health. Surgical management of otitis media with effusion in children. Clinical Guideline February 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG60fullguideline.pdf. [Last accessed August 2011]
   Google Scholar
• Kinane C, Gupta K. Residential care homes for the mentally ill. Implications for a catchment area service. Psych Bull 2001;25:61-6
   Google Scholar
• Klein JO. Otitis media. Clin Infect Dis 1994;19:823-33
   PubMed Web of Science ®Google Scholar
• Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:266-72
   PubMed Web of Science ®Google Scholar
• Murphy TF, Brauer AL, Sethi S, et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 2007;195:81-9
   PubMed Web of Science ®Google Scholar
• Shann F. Haemophilus influenzae pneumonia: type b or non-type b? Lancet 1999;354:1488-90
   PubMed Web of Science ®Google Scholar
• De Schutter I, De Wachter E, Crokaert F, et al. Microbiological results in Belgian children with non-responding or recurrent community acquired lower respiratory tract infection (CA-LRTI). Brussels, Belgium: ESPID, 2009
   Google Scholar
• Chiang WC, Teoh OH, Chong CY, et al. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirology 2007;12:254-61
   PubMed Web of Science ®Google Scholar
• Straus WL, Qazi SA, Kundi Z, et al. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Lancet 1998;352:270-4
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis 2009;48:57-64
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007;196:1346-54
   PubMed Web of Science ®Google Scholar
• Chen I, Knerer G, Hausdorff W. Herd protection following conjugate pneumococcal vaccination: perception and evidence. 3rd Vaccine Global Congress, Singapore, 4–6 October 2009. Abstract P2.42
   Google Scholar
• Palmu A, Jokinen J, Kilpi T. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 2008;26:2466-70
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010;340:c2509
   PubMed Web of Science ®Google Scholar
• Chuck AW, Jacobs P, Tyrrell G, et al. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010;28:5485-90
   PubMed Web of Science ®Google Scholar
• Beutels P, Van Damme P, Oosterhuis-Kafeja F. Effects and costs of pneumococcal conjugate vaccination of Belgian children. Knowledge Centre (KCE); 2006. KCE reports 33C (D/2006/10.273/53). Available at: kce.fgov.be/Download.aspx?ID=633. [Last accessed August 2011]
   Google Scholar
• Salo H, Sintonen H, Nuorti JP, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis 2005;37:821-32
   PubMed Web of Science ®Google Scholar
• Beutels P, Blommaert A, Hanquet G, et al. Rapport coût-efficacité des vaccins antipneumococciques conjugués 10-valent et 13-valent chez l’enfant. Health Technology Assessment (HTA). Bruxelles: Centre federal d’expertise des soins de santé (KCE), 2011. Reports 155B. D/2011/10.273/20. Available at: http://kce.fgov.be/index_fr.aspx?SGREF=3228&CREF=19992. Accessed August 2011
   Google Scholar
• Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283:1460-8
   PubMed Web of Science ®Google Scholar
• O’Brien MA, Prosser LA, Paradise JL, et al. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics 2009;123:1452-63
   PubMed Web of Science ®Google Scholar
• Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004;113:283-90
   PubMed Web of Science ®Google Scholar